• Explore /
  • Poster
  • / Addition of abiraterone to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Model to estimate long-term survival, quality-adjusted survival, and cost-effectiveness.

Addition of abiraterone to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Model to estimate long-term survival, quality-adjusted survival, and cost-effectiveness.

Abstract Poster

Authors

null

Caroline Sarah Clarke

University College London, London, United Kingdom

Caroline Sarah Clarke , Christopher D. Brawley , Fiona Caroline Ingleby , Andrea Gabrio , David P. Dearnaley , David Matheson , Gerhardt Attard , Hannah L. Rush , Robert J. Jones , Noel W. Clarke , Mahesh K. B. Parmar , Matthew R. Sydes , Rachael Maree Hunter , Nicholas D. James

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Other

Clinical Trial Registration Number

NCT00268476

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 204)

Abstract #

204

Poster Bd #

J18

Abstract Disclosures

Similar Posters

First Author: Maral DerSarkissian

First Author: Antonin Broyelle

First Author: Robert Stevenson

First Author: Elena Castro